LC-MS-Based Metabolomics Study of Marine Bacterial Secondary Metabolite and Antibiotic Production in Salinispora arenicola

被引:46
作者
Bose, Utpal [1 ]
Hewavitharana, Amitha K. [1 ]
Ng, Yi Kai [2 ]
Shaw, Paul Nicholas [1 ]
Fuerst, John A. [2 ]
Hodson, Mark P. [1 ,3 ]
机构
[1] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia
[2] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia
[3] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Metabol Australia, Brisbane, Qld 4072, Australia
关键词
Salinispora arenicola; salt concentration; antibiotic; metabolomics; secondary metabolites; liquid chromatography; mass spectrometry; multivariate analysis; SPONGE PSEUDOCERATINA-CLAVATA; TROPICA STRAIN NPS21184; NATURAL-PRODUCTS; SALINOSPORAMIDE-A; SP NOV; ACTINOMYCETE; ACTINOBACTERIA; RIFAMYCINS; DISCOVERY; GROWTH;
D O I
10.3390/md13010249
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
An LC-MS-based metabolomics approach was used to characterise the variation in secondary metabolite production due to changes in the salt content of the growth media as well as across different growth periods (incubation times). We used metabolomics as a tool to investigate the production of rifamycins (antibiotics) and other secondary metabolites in the obligate marine actinobacterial species Salinispora arenicola, isolated from Great Barrier Reef (GBR) sponges, at two defined salt concentrations and over three different incubation periods. The results indicated that a 14 day incubation period is optimal for the maximum production of rifamycin B, whereas rifamycin S and W achieve their maximum concentration at 29 days. A "chemical profile" link between the days of incubation and the salt concentration of the growth medium was shown to exist and reliably represents a critical point for selection of growth medium and harvest time.
引用
收藏
页码:249 / 266
页数:18
相关论文
共 64 条
[1]   Salinispora pacifica sp nov., an actinomycete from marine sediments [J].
Ahmed, Lina ;
Jensen, Paul R. ;
Freel, Kelle C. ;
Brown, Ros ;
Jones, Amanda L. ;
Kim, Byung-Yong ;
Goodfellow, Michael .
ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY, 2013, 103 (05) :1069-1078
[2]  
[Anonymous], A VANLEEUWENHOEK
[3]   Rifamycins - Obstacles and opportunities [J].
Aristoff, Paul A. ;
Garcia, George A. ;
Kirchhoff, Paul D. ;
Showalter, H. D. Hollis .
TUBERCULOSIS, 2010, 90 (02) :94-118
[4]   BIOTRANSFORMATIONS OF RIFAMYCINS - PROCESS POSSIBILITIES [J].
BANERJEE, UC ;
SAXENA, B ;
CHISTI, Y .
BIOTECHNOLOGY ADVANCES, 1992, 10 (04) :577-595
[5]  
Bernan VS, 1997, ADV APPL MICROBIOL, V43, P57, DOI 10.1016/S0065-2164(08)70223-5
[6]   Marine natural products [J].
Blunt, John W. ;
Copp, Brent R. ;
Hu, Wan-Ping ;
Munro, Murray H. G. ;
Northcote, Peter T. ;
Prinsep, Michele R. .
NATURAL PRODUCT REPORTS, 2008, 25 (01) :35-94
[7]   Marine natural products [J].
Blunt, John W. ;
Copp, Brent R. ;
Hu, Wan-Ping ;
Munro, Murray H. G. ;
Northcote, Peter T. ;
Prinsep, Michele R. .
NATURAL PRODUCT REPORTS, 2007, 24 (01) :31-86
[8]  
Blunt JW, 2013, NAT PROD REP, V30, P237, DOI [10.1039/d0np00089b, 10.1039/c2np20112g]
[9]   Marine natural products [J].
Blunt, John W. ;
Copp, Brent R. ;
Munro, Murray H. G. ;
Northcote, Peter T. ;
Prinsep, Michele R. .
NATURAL PRODUCT REPORTS, 2011, 28 (02) :196-268
[10]   Marine natural products [J].
Blunt, John W. ;
Copp, Brent R. ;
Munro, Murray H. G. ;
Northcote, Peter T. ;
Prinsep, Michele R. .
NATURAL PRODUCT REPORTS, 2010, 27 (02) :165-237